|
1
|
Yu M, Ting DT, Stott SL, et al: RNA
sequencing of pancreatic circulating tumour cells implicates WNT
signalling in metastasis. Nature. 487:510–513. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar
|
|
3
|
Deng H, Wang HF, Gao YB, Jin XL and Xiao
JC: Hepatic progenitor cell represents a transitioning cell
population between liver epithelium and stroma. Med Hypotheses.
76:809–812. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Armstrong AJ, Marengo MS, Oltean S, et al:
Circulating tumor cells from patients with advanced prostate and
breast cancer display both epithelial and mesenchymal markers. Mol
Cancer Res. 9:997–1007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bednarz N, Eltze E, Semjonow A, et al:
BRCA1 loss preexisting in small subpopulations of prostate cancer
is associated with advanced disease and metastatic spread to lymph
nodes and peripheral blood. Clin Cancer Res. 16:3340–3348. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joosse SA, Hannemann J, Spotter J, et al:
Changes in keratin expression during metastatic progression of
breast cancer: impact on the detection of circulating tumor cells.
Clin Cancer Res. 18:993–1003. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bednarz-Knoll N, Alix-Panabières C and
Pantel K: Plasticity of disseminating cancer cells in patients with
epithelial malignancies. Cancer Metastasis Rev. 31:673–687. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gradilone A, Raimondi C, Nicolazzo C, et
al: Circulating tumour cells lacking cytokeratin in breast cancer:
the importance of being mesenchymal. J Cell Mol Med. 15:1066–1070.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013.PubMed/NCBI
|
|
11
|
Gay LJ and Felding-Habermann B:
Contribution of platelets to tumour metastasis. Nat Rev Cancer.
11:123–134. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Labelle M, Begum S and Hynes RO: Direct
signaling between platelets and cancer cells induces an
epithelial-mesenchymal-like transition and promotes metastasis.
Cancer Cell. 20:576–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Assoian RK, Komoriya A, Meyers CA, Miller
DM and Sporn MB: Transforming growth factor-beta in human
platelets. Identification of a major storage site, purification,
and characterization. J Biol Chem. 258:7155–7160. 1983.PubMed/NCBI
|
|
14
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View
Article : Google Scholar
|
|
15
|
Bao B, Wang Z, Ali S, et al: Notch-1
induces epithelial-mesenchymal transition consistent with cancer
stem cell phenotype in pancreatic cancer cells. Cancer Lett.
307:26–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong D, Wang Z, Sarkar SH, et al:
Platelet-derived growth factor-D overexpression contributes to
epithelial-mesenchymal transition of PC3 prostate cancer cells.
Stem Cells. 26:1425–1435. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmad A, Wang Z, Kong D, et al:
Platelet-derived growth factor-D contributes to aggressiveness of
breast cancer cells by up-regulating Notch and NF-kappaB signaling
pathways. Breast Cancer Res Treat. 126:15–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu J, Liao S, Huang Y, et al: PDGF-D
improves drug delivery and efficacy via vascular normalization, but
promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Clin Cancer Res. 17:3638–3648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jechlinger M, Sommer A, Moriggl R, et al:
Autocrine PDGFR signaling promotes mammary cancer metastasis. J
Clin Invest. 116:1561–1570. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gotzmann J, Fischer AN, Zojer M, et al: A
crucial function of PDGF in TGF-beta-mediated cancer progression of
hepatocytes. Oncogene. 25:3170–3185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jechlinger M, Grunert S, Tamir IH, et al:
Expression profiling of epithelial plasticity in tumor progression.
Oncogene. 22:7155–7169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lahsnig C, Mikula M, Petz M, et al: ILEI
requires oncogenic Ras for the epithelial to mesenchymal transition
of hepatocytes and liver carcinoma progression. Oncogene.
28:638–650. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fischer AN, Fuchs E, Mikula M, Huber H,
Beug H and Mikulits W: PDGF essentially links TGF-beta signaling to
nuclear beta-catenin accumulation in hepatocellular carcinoma
progression. Oncogene. 26:3395–3405. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bruna A, Darken RS, Rojo F, et al: High
TGFbeta-Smad activity confers poor prognosis in glioma patients and
promotes cell proliferation depending on the methylation of the
PDGF-B gene. Cancer Cell. 11:147–160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Flossmann E and Rothwell PM; British
Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of
aspirin on long-term risk of colorectal cancer: consistent evidence
from randomised and observational studies. Lancet. 369:1603–1613.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rothwell PM, Wilson M, Elwin CE, et al:
Long-term effect of aspirin on colorectal cancer incidence and
mortality: 20-year follow-up of five randomised trials. Lancet.
376:1741–1750. 2010.PubMed/NCBI
|
|
27
|
Rothwell PM, Fowkes FG, Belch JF, Ogawa H,
Warlow CP and Meade TW: Effect of daily aspirin on long-term risk
of death due to cancer: analysis of individual patient data from
randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rothwell PM, Price JF, Fowkes FG, et al:
Short-term effects of daily aspirin on cancer incidence, mortality,
and non-vascular death: analysis of the time course of risks and
benefits in 51 randomised controlled trials. Lancet. 379:1602–1612.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rothwell PM, Wilson M, Price JF, Belch JF,
Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer
metastasis: a study of incident cancers during randomised
controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patrono C, Garcia Rodriguez LA, Landolfi R
and Baigent C: Low-dose aspirin for the prevention of
atherothrombosis. N Engl J Med. 353:2373–2383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Laubli H, Stevenson JL, Varki A, Varki NM
and Borsig L: L-selectin facilitation of metastasis involves
temporal induction of Fut7-dependent ligands at sites of tumor cell
arrest. Cancer Res. 66:1536–1542. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Serebruany VL, Steinhubl SR, Berger PB, et
al: Analysis of risk of bleeding complications after different
doses of aspirin in 192,036 patients enrolled in 31 randomized
controlled trials. Am J Cardiol. 95:1218–1222. 2005. View Article : Google Scholar
|
|
33
|
Peters RJ, Mehta SR, Fox KA, et al:
Effects of aspirin dose when used alone or in combination with
clopidogrel in patients with acute coronary syndromes: observations
from the Clopidogrel in Unstable angina to prevent Recurrent Events
(CURE) study. Circulation. 108:1682–1687. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Topol EJ, Easton D, Harrington RA, et al:
Randomized, double-blind, placebo-controlled, international trial
of the oral IIb/IIIa antagonist lotrafiban in coronary and
cerebrovascular disease. Circulation. 108:399–406. 2003. View Article : Google Scholar
|
